IL-17 ELISpot as Predictor for Kidney Allograft Rejection?

Area of Science:

• Immunology
• Transplantation Science
• Clinical Research

Background:

• Interleukin-17 (IL-17) expression in kidney biopsies has been linked to predicting allograft rejection.
• Assessing IL-17A responses may offer insights into transplant outcomes.

Purpose of the Study:

• To test if IL-17A ELISpot responses predict acute kidney allograft rejection.
• To evaluate the utility of pre-transplant IL-17A ELISpot assays in kidney transplant recipients.

Main Methods:

• IL-17A ELISpot assays were conducted on 50 kidney transplant recipients before surgery.
• Seventeen recipients experienced acute allograft rejection post-transplant.
• Assays measured IL-17A-producing T cells in response to third-party cells and mitogens.

Main Results:

• No significant difference in IL-17A-producing T cells was observed between recipients with and without rejection.
• Pre-transplant alloreactivity correlated with reactivity to phytohemagglutinin (PHA).

Conclusions:

• IL-17A ELISpot assays were not predictive of acute kidney allograft rejection.
• ELISpots stimulated with allogeneic cells or PHA can indicate general T-cell IL-17A secretion capacity.